Pfizer (NYSE:PFE) Trading 2.2% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE)’s share price traded up 2.2% during trading on Monday . The stock traded as high as $23.93 and last traded at $23.86. 11,502,318 shares were traded during trading, a decline of 72% from the average session volume of 40,908,650 shares. The stock had previously closed at $23.35.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Trading Up 3.3%

The business has a 50-day moving average of $22.95 and a 200-day moving average of $25.00. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $137.16 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.13%. Pfizer’s payout ratio is presently 124.64%.

Institutional Trading of Pfizer

Hedge funds have recently added to or reduced their stakes in the business. Tallon Kerry Patrick acquired a new stake in Pfizer in the 4th quarter worth $509,000. Brighton Jones LLC grew its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Silver Oak Securities Incorporated raised its holdings in Pfizer by 13.7% in the 4th quarter. Silver Oak Securities Incorporated now owns 15,886 shares of the biopharmaceutical company’s stock valued at $420,000 after acquiring an additional 1,919 shares in the last quarter. Finally, Strategic Financial Concepts LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $2,281,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.